Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

B7-H3-targeted radioimmunotherapy of human cancer.

Kasten BB, Ferrone S, Zinn KR, Buchsbaum DJ.

Curr Med Chem. 2019 Feb 28. doi: 10.2174/0929867326666190228120908. [Epub ahead of print]

PMID:
30836909
2.

The antitumor effects of entinostat in ovarian cancer require adaptive immunity.

Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC.

Cancer. 2018 Dec 15;124(24):4657-4666. doi: 10.1002/cncr.31761. Epub 2018 Nov 13.

PMID:
30423192
3.

Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling.

Budhwani KI, Oliver PG, Buchsbaum DJ, Thomas V.

Adv Exp Med Biol. 2018;1077:87-113. doi: 10.1007/978-981-13-0947-2_6.

PMID:
30357685
4.

The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.

McCaw TR, Li M, Starenki D, Cooper SJ, Liu M, Meza-Perez S, Arend RC, Buchsbaum DJ, Forero A, Randall TD.

Cancer Immunol Immunother. 2019 Feb;68(2):175-188. doi: 10.1007/s00262-018-2262-5. Epub 2018 Oct 17.

PMID:
30334128
5.

Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.

Gangrade A, Pathak V, Augelli-Szafran CE, Wei HX, Oliver P, Suto M, Buchsbaum DJ.

Int J Mol Sci. 2018 May 20;19(5). pii: E1524. doi: 10.3390/ijms19051524.

6.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

7.

Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73].

Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2018 Jun;61:71. doi: 10.1016/j.nucmedbio.2018.03.004. Epub 2018 Apr 25. No abstract available.

PMID:
29705525
8.

Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.

Fancy RM, Kim H, Napier T, Buchsbaum DJ, Zinn KR, Song Y.

J Cell Biochem. 2018 Jul;119(7):6216-6230. doi: 10.1002/jcb.26848. Epub 2018 Apr 16.

9.

Retraction notice to "SRI36160 is a specific inhibitor of Wnt/<beta>-catenin signaling in human pancreatic and colorectal cancer cells" [Canc. Lett. 389C (2017) 41-48].

Li Y, Oliver PG, Lu W, Pathak V, Sridharan S, Augelli-Szafran CE, Buchsbaum DJ, Suto MJ.

Cancer Lett. 2018 May 28;422:131. doi: 10.1016/j.canlet.2018.03.017. No abstract available.

10.

212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.

Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.

Int J Mol Sci. 2018 Mar 21;19(4). pii: E925. doi: 10.3390/ijms19040925.

11.

CD38 pretargeted RIT of B-cell tumors.

Buchsbaum DJ.

Blood. 2018 Feb 8;131(6):589-590. doi: 10.1182/blood-2017-12-819011. No abstract available.

12.

212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.

Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2018 Mar;58:67-73. doi: 10.1016/j.nucmedbio.2017.12.004. Epub 2017 Dec 24. Erratum in: Nucl Med Biol. 2018 Apr 25;:.

13.

ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.

Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, Buchsbaum DJ, Bellis SL.

J Biol Chem. 2018 Jan 19;293(3):984-994. doi: 10.1074/jbc.M117.808584. Epub 2017 Nov 30.

14.

Modulation of antitumor immunity with histone deacetylase inhibitors.

McCaw TR, Randall TD, Forero A, Buchsbaum DJ.

Immunotherapy. 2017 Dec;9(16):1359-1372. doi: 10.2217/imt-2017-0134. Review.

15.

Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.

Naoum GE, Buchsbaum DJ, Tawadros F, Farooqi A, Arafat WO.

Oncol Rev. 2017 Apr 28;11(1):332. doi: 10.4081/oncol.2017.332. eCollection 2017 Mar 3. Review.

16.

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM Jr, Buchsbaum DJ, Randall TD, Arend RC.

Oncotarget. 2017 Jul 4;8(27):44159-44170. doi: 10.18632/oncotarget.17395.

17.

Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.

Smith HJ, Straughn JM, Buchsbaum DJ, Arend RC.

Gynecol Oncol Rep. 2017 Mar 21;20:81-86. doi: 10.1016/j.gore.2017.03.007. eCollection 2017 May. Review.

18.

Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.

Naoum GE, Zhu ZB, Buchsbaum DJ, Curiel DT, Arafat WO.

Clin Transl Med. 2017 Dec;6(1):11. doi: 10.1186/s40169-017-0140-y. Epub 2017 Mar 1.

19.

Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer".

Pathak V, Augelli-Szafran CE, Wei HX, Li Y, Oliver PG, Lu W, Buchsbaum DJ, Suto MJ.

J Med Chem. 2017 Sep 14;60(17):7615. doi: 10.1021/acs.jmedchem.6b01417. No abstract available.

PMID:
28230988
20.

B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.

Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.

21.

Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.

Fancy RM, Kim H, Zhou T, Zinn KR, Buchsbaum DJ, Song Y.

J Cell Biochem. 2017 Aug;118(8):2285-2294. doi: 10.1002/jcb.25882. Epub 2017 Apr 12.

22.

SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.

Li Y, Oliver PG, Lu W, Pathak V, Sridharan S, Augelli-Szafran CE, Buchsbaum DJ, Suto MJ.

Cancer Lett. 2017 Mar 28;389:41-48. doi: 10.1016/j.canlet.2016.12.030. Epub 2016 Dec 30. Retraction in: Cancer Lett. 2018 May 28;422:131.

23.

Genomic regulation of invasion by STAT3 in triple negative breast cancer.

McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, Oliver PG, Sexton KC, Grizzle WE, Forero A, Buchsbaum DJ, Cooper SJ, Myers RM.

Oncotarget. 2017 Jan 31;8(5):8226-8238. doi: 10.18632/oncotarget.14153.

24.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459.

25.
26.

Role of nanotechnology and gene delivery systems in TRAIL-based therapies.

Naoum GE, Tawadros F, Farooqi AA, Qureshi MZ, Tabassum S, Buchsbaum DJ, Arafat W.

Ecancermedicalscience. 2016 Aug 1;10:660. doi: 10.3332/ecancer.2016.660. eCollection 2016. Review.

27.

RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.

Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, Posey JA, Grizzle WE, Vickers SM, Buchsbaum DJ, Cooper SJ, Myers RM.

Mol Oncol. 2016 Oct;10(8):1169-82. doi: 10.1016/j.molonc.2016.05.004. Epub 2016 May 26.

28.

The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.

Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, Conner MG, Arend RC, Yoon KJ, Klug CA, Bullard DC, Kesterson RA, Oliver PG, O'Connor AK, Yoder BK, Bellis SL.

Cancer Res. 2016 Jul 1;76(13):3978-88. doi: 10.1158/0008-5472.CAN-15-2834. Epub 2016 May 23.

29.

Ovarian cancer and the immune system - The role of targeted therapies.

Turner TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, Arend RC.

Gynecol Oncol. 2016 Aug;142(2):349-56. doi: 10.1016/j.ygyno.2016.05.007. Epub 2016 May 23. Review.

PMID:
27174875
30.
31.

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.

Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE.

Cancer Immunol Res. 2016 May;4(5):390-9. doi: 10.1158/2326-6066.CIR-15-0243. Epub 2016 Mar 15.

32.

Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.

Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, Buchsbaum DJ, Samant RS, Shevde LA.

Oncotarget. 2016 Apr 5;7(14):17991-8005. doi: 10.18632/oncotarget.7494.

33.

Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.

Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade A, Straughn JM Jr, Buchsbaum DJ.

Lab Invest. 2016 Feb;96(2):249-59. doi: 10.1038/labinvest.2015.150. Epub 2015 Dec 14.

34.

Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer.

Ludwig MR, Kojima K, Bowersock GJ, Chen D, Jhala NC, Buchsbaum DJ, Grizzle WE, Klug CA, Mobley JA.

Proteomics. 2016 Feb;16(3):516-31. doi: 10.1002/pmic.201500133. Epub 2016 Jan 18.

PMID:
26572242
35.
36.

Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.

Arafat W, Zhou T, Naoum GE, Buchsbaum DJ.

J Egypt Natl Canc Inst. 2015 Dec;27(4):205-15. doi: 10.1016/j.jnci.2015.08.003. Epub 2015 Sep 16.

37.

Niclosamide Analogs for Treatment of Ovarian Cancer.

Walters Haygood CL, Arend RC, Gangrade A, Chettiar S, Regan N, Hassmann CJ 2nd, Li PK, Hidalgo B, Straughn JM Jr, Buchsbaum DJ.

Int J Gynecol Cancer. 2015 Oct;25(8):1377-85. doi: 10.1097/IGC.0000000000000506.

PMID:
26186072
38.

Ovarian and cervical cancer patient derived xenografts: The past, present, and future.

Boone JD, Dobbin ZC, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2015 Aug;138(2):486-91. doi: 10.1016/j.ygyno.2015.05.022. Epub 2015 May 27. Review.

PMID:
26026736
39.

Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model.

Kim H, Samuel S, Totenhagen JW, Warren M, Sellers JC, Buchsbaum DJ.

J Vis Exp. 2015 Apr 18;(98). doi: 10.3791/52641.

40.

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.

Che P, Yang Y, Han X, Hu M, Sellers JC, Londono-Joshi AI, Cai GQ, Buchsbaum DJ, Christein JD, Tang Q, Chen D, Li Q, Grizzle WE, Lu YY, Ding Q.

Sci Rep. 2015 Feb 13;5:8453. doi: 10.1038/srep08453.

41.

Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ.

World J Stem Cells. 2014 Sep 26;6(4):441-7. doi: 10.4252/wjsc.v6.i4.441. Review.

42.

Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

Kim H, Samuel SL, Zhai G, Rana S, Taylor M, Umphrey HR, Oelschlager DK, Buchsbaum DJ, Zinn KR.

Cancer Biol Ther. 2014 Aug;15(8):1053-60. doi: 10.4161/cbt.29183.

43.

Pazopanib combined with radiation: in vivo model of interaction.

Meredith RF, Raisch KP, Bonner JA, Buchsbaum DJ, Grizzle WE, Li Y, Spencer SA.

Cancer Biother Radiopharm. 2014 Aug;29(6):247-50. doi: 10.1089/cbr.2013.1583. Epub 2014 Jun 19.

PMID:
24945464
44.

Recurrent read-through fusion transcripts in breast cancer.

Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A, Buchsbaum DJ, LoBuglio AF, Myers RM.

Breast Cancer Res Treat. 2014 Jul;146(2):287-97. doi: 10.1007/s10549-014-3019-2. Epub 2014 Jun 15.

45.

Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.

Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Curiel DT.

Cancer Gene Ther. 2014 Jul;21(7):264-74. doi: 10.1038/cgt.2014.26. Epub 2014 Jun 6.

46.

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ.

Gynecol Oncol. 2014 Jul;134(1):112-20. doi: 10.1016/j.ygyno.2014.04.005. Epub 2014 Apr 13.

PMID:
24736023
47.

Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.

Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ.

Cancer Lett. 2014 Jul 10;349(1):8-14. doi: 10.1016/j.canlet.2014.04.003. Epub 2014 Apr 13. Review.

48.

Effect of niclosamide on basal-like breast cancers.

Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ.

Mol Cancer Ther. 2014 Apr;13(4):800-11. doi: 10.1158/1535-7163.MCT-13-0555. Epub 2014 Feb 19.

49.

Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer?

Buchsbaum DJ, Croce CM.

JAMA. 2014 Jan 22-29;311(4):363-5. doi: 10.1001/jama.2013.284665. No abstract available.

50.

Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.

Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM Jr, Landen CN, Ferrone S, Buchsbaum DJ.

Gynecol Oncol. 2014 Jan;132(1):203-10. doi: 10.1016/j.ygyno.2013.10.038. Epub 2013 Nov 9.

PMID:
24216048

Supplemental Content

Loading ...
Support Center